



Published on *Drug Pipeline* (<https://www.drugpipeline.net>)

Home > Ischemia Reperfusion Injury - Pipeline Review, H1 2019

Ischemia Reperfusion Injury - Pipeline Review, H1 2019

Publication ID:

GMD0319001

Publication Date:

March 18, 2019

Pages:

163

Publisher:

Global Markets Direct

Region:

Global [1]

\$2,000.00

Publication License Type *

Single User License (PDF), \$2,000.00

Site License (PDF), \$4,000.00

Global License (PDF), \$6,000.00

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.

Add to cart



Description:

Ischemia Reperfusion Injury - Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ischemia Reperfusion Injury - Pipeline Review, H1 2019, provides an overview of the Ischemia Reperfusion Injury (Cardiovascular) pipeline landscape.

Ischemic reperfusion injury is the tissue damage that happens when blood supply returns to the tissue after a period of lack of oxygen. The absence of oxygen and nutrients creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative. Symptoms include headache, bradycardia, seizures and hypertension. Risk factors include hypertension, hyperlipidemia, diabetes, insulin resistance, heart failure, altered coronary circulation, and aging.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ischemia Reperfusion Injury - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ischemia Reperfusion Injury (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Ischemia Reperfusion Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 4, 34 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 17 and 1 molecules, respectively.

Ischemia Reperfusion Injury (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ischemia Reperfusion Injury (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Ischemia Reperfusion Injury (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ischemia Reperfusion Injury (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ischemia Reperfusion Injury (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ischemia Reperfusion Injury (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ischemia Reperfusion Injury (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents:

Table of Contents

Introduction

Ischemia Reperfusion Injury - Overview

Ischemia Reperfusion Injury - Therapeutics Development
Ischemia Reperfusion Injury - Therapeutics Assessment
Ischemia Reperfusion Injury - Companies Involved in Therapeutics Development
Ischemia Reperfusion Injury - Drug Profiles
Ischemia Reperfusion Injury - Dormant Projects
Ischemia Reperfusion Injury - Discontinued Products
Ischemia Reperfusion Injury - Product Development Milestones
Appendix

List of Tables

List of Tables

Number of Products under Development for Ischemia Reperfusion Injury, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Products under Development by Companies, H1 2019 (Contd..2), H1 2019
Products under Development by Universities/Institutes, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Target, H1 2019 (Contd..1), H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019 (Contd..1), H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Ischemia Reperfusion Injury - Pipeline by Akashi Therapeutics Inc, H1 2019
Ischemia Reperfusion Injury - Pipeline by Argenx SE, H1 2019
Ischemia Reperfusion Injury - Pipeline by Balmes Transplantation SAS, H1 2019
Ischemia Reperfusion Injury - Pipeline by Bolder Biotechnology Inc, H1 2019
Ischemia Reperfusion Injury - Pipeline by Catalyst Biosciences Inc, H1 2019
Ischemia Reperfusion Injury - Pipeline by Celdara Medical LLC, H1 2019
Ischemia Reperfusion Injury - Pipeline by Cellmid Ltd, H1 2019
Ischemia Reperfusion Injury - Pipeline by CFM Pharma Holding BV, H1 2019
Ischemia Reperfusion Injury - Pipeline by Conatus Pharmaceuticals Inc, H1 2019
Ischemia Reperfusion Injury - Pipeline by Corline Biomedical AB, H1 2019
Ischemia Reperfusion Injury - Pipeline by Gilead Sciences Inc, H1 2019
Ischemia Reperfusion Injury - Pipeline by Glucox Biotech AB, H1 2019
Ischemia Reperfusion Injury - Pipeline by Ischemix Inc, H1 2019
Ischemia Reperfusion Injury - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2019
Ischemia Reperfusion Injury - Pipeline by LG Chem Ltd, H1 2019

Ischemia Reperfusion Injury - Pipeline by Mallinckrodt Plc, H1 2019
Ischemia Reperfusion Injury - Pipeline by NovelMed Therapeutics Inc, H1 2019
Ischemia Reperfusion Injury - Pipeline by Pfizer Inc, H1 2019
Ischemia Reperfusion Injury - Pipeline by Radikal Therapeutics Inc, H1 2019
Ischemia Reperfusion Injury - Pipeline by Reata Pharmaceuticals Inc, H1 2019
Ischemia Reperfusion Injury - Pipeline by SBI Pharmaceuticals Co Ltd, H1 2019
Ischemia Reperfusion Injury - Pipeline by Stealth BioTherapeutics Corp, H1 2019
Ischemia Reperfusion Injury - Dormant Projects, H1 2019
Ischemia Reperfusion Injury - Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development for Ischemia Reperfusion Injury, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Top 10 Molecule Types, H1 2019

Number of Products by Stage and Top 10 Molecule Types, H1 2019

Companies Mentioned:

Akashi Therapeutics Inc

Argenx SE

Balmes Transplantation SAS

Bolder Biotechnology Inc

Catalyst Biosciences Inc

Celdara Medical LLC

Cellmid Ltd

CFM Pharma Holding BV

Conatus Pharmaceuticals Inc

Corline Biomedical AB

Gilead Sciences Inc

Glucox Biotech AB

Ischemix Inc

Lee's Pharmaceutical Holdings Ltd

LG Chem Ltd

Mallinckrodt Plc

NovelMed Therapeutics Inc
Pfizer Inc
Radikal Therapeutics Inc
Reata Pharmaceuticals Inc
SBI Pharmaceuticals Co Ltd
Stealth BioTherapeutics Corp

License Types:

Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but

may not share the publication (or any information contained therein) with any other person or persons outside of the organization.

- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.



No. 1101, Golden Square, 3rd Floor,
24th Main, J P Nagar, 1st Phase,
Bangalore, Karnataka, India- 560078

India: +91-8762746600

info@domain.com

-->

NAVIGATE

[About Us](#)

[Reports by Region](#)

[FAQ](#)

[Privacy Policy](#)

[TERMS & CONDITIONS](#)

[CONTACT](#)

RECENT POSTS

[What is drug pipeline research?](#)

March 20

[How to use market research to bring your idea to life?](#)

March 11

[How to gain business insights using syndicated market research?](#)

March 10

Source URL: <https://www.drugpipeline.net/global-markets-direct/ischemia-reperfusion-injury-pipeline-review-h1-2019>

Links

[1] <https://www.drugpipeline.net/region/global>